News
HanchorBio Expands Clinical Evidence Supporting Its Macrophage-Directed Oncology Strategy
HanchorBio announced updated early clinical observations from its HCB101 program.
Jul 22, 2026
Read more
HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors
HanchorBio announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).
Jul 08, 2026
Read more
HanchorBio Announces FDA Type C Meeting Minutes Supporting a Clear Development Path for HCB101 in Second-Line Gastric/GEJ Cancer
HanchorBio announced receipt of the official minutes from its recent U.S. Food and Drug Administration (FDA) Type C meeting regarding the post-Phase 1 development strategy for HCB101.
Jun 30, 2026
Read more
HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline
HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
Jun 13, 2026
Read more
HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease
HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
Jun 10, 2026
Read more
HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress
HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Jun 01, 2026
Read more
HanchorBio Announces First Confirmed Partial Response in Colorectal Cancer Cohort of Ongoing HCB101-201 Combination Study
HanchorBio announced the first confirmed partial response (PR) in the colorectal cancer (CRC) cohort of its ongoing clinical study evaluating HCB101 in combination with standard-of-care regimens (NCT06771622).
May 18, 2026
Read more
HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances Key Preclinical Studies
HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.
May 11, 2026
Read more
HanchorBio Launches HCB101 Mechanism Collaboration Study with the Institute of Tsinghua University, Hebei
HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.
May 05, 2026
Read more
HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics
HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.
Apr 29, 2026
Read more